# a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer

> **NCT04790539** · PHASE2 · UNKNOWN · sponsor: **Shanghai Pulmonary Hospital, Shanghai, China** · enrollment: 71 (estimated)

## Conditions studied

- Extensive Stage Small Cell Lung Cancer

## Interventions

- **DRUG:** SHR-1210

## Key facts

- **NCT ID:** NCT04790539
- **Lead sponsor:** Shanghai Pulmonary Hospital, Shanghai, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-01
- **Primary completion:** 2022-05-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2021-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04790539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04790539, "a Study of SHR1210 in Combination With Paclitaxel-albumin and Carboplatin in Extensive Stage Small Cell Lung Cancer". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT04790539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*